Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Clinical Trial
Official title:
CIDP07 Rozanolixizumab Post Trial Access Program (the PTA)
This Post Trial Access (PTA) Program enables access to rozanolixizumab for eligible patients who have taken part in the CIDP04 trial (NCT04051944) and are continuing to derive benefit from treatment.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06040567 -
Polyneuropathy, Impairments and Physical Activity - The PolyImPAct Study
|
||
Active, not recruiting |
NCT04280718 -
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)
|
Phase 2 | |
Recruiting |
NCT05492604 -
Comparison of FEETME® Soles and GAITRITE® Walkway for the Evaluation of Gait Disorders in CIDP.
|
N/A | |
Not yet recruiting |
NCT03166527 -
Panzyga in CIDP Administered at Different Infusion Rates
|
Phase 3 | |
Completed |
NCT02027701 -
Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
|
Phase 3 | |
Completed |
NCT04281472 -
A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)
|
Phase 2 |